phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Oxeia Pioneering First Potential FDA-Approved Concussion Treatment

Oxeia Biopharmaceuticals today launched an equity crowdfunding campaign on StartEngine to advance OXE103, a therapy for persistent concussion symptoms that demonstrated an 85% responder rate in Phase 2a clinical testing.

January 7, 2026


January 8 2026

January 7 2026

January 6 2026

January 5 2026

January 4 2026

January 3 2026

January 2 2026

January 1 2026

December 31 2025

December 30 2025

December 29 2025

December 28 2025

December 27 2025

December 26 2025

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy